Remus Pharmaceuticals (NSE:REMUS) EBIT: ₹606 Mil (TTM As of Mar. 2026)


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
55 GF Score
Price ₹793.70
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals EBIT?

Remus Pharmaceuticals NSE:REMUS -1.02% 55 EBIT is ₹606 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Remus Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹321 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹606 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Remus Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was 10.51%. Remus Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 61.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Remus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.42%.

Remus Pharmaceuticals  (NSE:REMUS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Remus Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=566 * ( 1 - 21.37% )/( (4054.6 + 4410.9)/ 2 )
=445.0458/4232.75
=10.51 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5682.1 - 1306.1 - ( 321.4 - max(0, 1949.2 - 3131.2+321.4))
=4054.6

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5786.5 - 826.5 - ( 549.1 - max(0, 1491 - 2946.4+549.1))
=4410.9

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Remus Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=641.6/( ( (90.5 + max(826.8, 0)) + (178 + max(993.6, 0)) )/ 2 )
=641.6/( ( 917.3 + 1171.6 )/ 2 )
=641.6/1044.45
=61.43 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1476.6 + 1055.3 + 149.3) - (1306.1 + 0 + 548.3)
=826.8

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1398.4 + 720.6 + 181.8) - (826.5 + 0 + 480.7)
=993.6

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Remus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=606.3/9441.961
=6.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals EBIT Related Terms

Remus Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals EBIT Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 46.26 0.00 306.70 488.00 606.30

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 201.65 228.10 259.90 285.50 320.80

NSE:REMUS vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, Remus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Remus Pharmaceuticals EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Remus Pharmaceuticals's EV-to-EBIT falls into.


NSE:REMUS
55GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹606 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹606 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a EBIT of ₹606 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Remus Pharmaceuticals.
Is Remus Pharmaceuticals' EBIT too high?
Remus Pharmaceuticals' current EBIT is ₹606 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' EBIT compare to MCK and COR?
Remus Pharmaceuticals' EBIT of ₹606 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Remus Pharmaceuticals. Remus Pharmaceuticals's current EBIT is ₹606 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹793.70 — trading 61.7% below its estimated fair value. The current EBIT is ₹606 Mil. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current EBIT is ₹606 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • EBIT: ₹606 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score

Get the complete analysis for NSE:REMUS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹793.70
Price
₹2,071.36
GF Value